Congratulations to Dr. Paul Sondel who has awarded an inaugural Outstanding Investigator Award (OIA) from the National Cancer Institute (NCI).
Dr. Sondel is a Professor of pediatrics, human oncology and genetics at University of Wisconsin Madison School of Medicine and Public Health as well as a member of our Scientific Advisory Board at Quintessence. Dr. Sondel’s research focuses on the development of immunotherapies to treat cancer. More information about the award can be found here.
About Quintessence Biosciences Quintessence Biosciences, Inc. is a private company developing novel anti-cancer compounds based on our patented EVade™ Ribonuclease technology. The drug is differentiated, targeting the RNA in cancer cells. Dose escalation of our most advanced lead candidate, QBI-139, in a Phase I trial has recently been completed. The safety profile of the drug is distinct from chemotherapy. Based on encouraging signs of efficacy, partners are being sought for expansion cohorts to evaluate efficacy of QBI-139 in defined patient populations. The drug had a strong therapeutic window against a variety of in vivo xenograft models including: colon, non-small cell lung, ovarian, pancreatic and prostate cancer.
15 June 2012 - Quintessence Biosciences Meeting with Partners at 2012 BIO International Convention
31 May 2012 - Quintessence Biosciences Presents on Phase I trial of Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Annual Meeting
19 April 2012 - Quintessence Biosciences Selected for Buzz of BIO at 2012 BIO International Convention
12 April 2012 - Quintessence Biosciences Announces Election of Walter Dewey to Board of Directors
30 March 2012 - Quintessence Biosciences Presents Results for Combination Studies of Clinical Stage Ribonuclease QBI-139 at AACR Meeting
15 January 2010 - Quintessence Biosciences to Present at Keystone Symposia's RNA Silencing Conference